Share this story:

Veritas to Present at The Planet Microcap Showcase 2017 in Las Vegas; to Attend the Canadian Cannabis Business Conference In Toronto; and Supports Proposed Cannabis Legislation



April 19, 2017 / TheNewswire / Vancouver, B.C. - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that CEO and President, Dr. Lui Franciosi will present at The Planet Microcap Showcase 2017 alongside a panel of executives active in the development of cannabis related products.

The Showcase takes place April 26-28, 2017 at Planet Hollywood Resort & Casino in Las Vegas, Nevada. www.PlanetMicroCapShowcase.com. It brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking. The attendees include executives, investors, financial professionals and industry leaders. Veritas' CEO, Dr. Lui Franciosi commented, "We are pleased with the invitation to participate at The Planet Microcap Showcase, alongside the wide variety of panel members and keynote speakers in furthering the conversation into the medicinal cannabis."

Dr. Franciosi will also be attending the Canadian Cannabis Business Conference from May 23 to 26 in Toronto, www.CanadianInstitute.com/Canadian-Cannabis-Business-Conference The Conference will examine the different aspects of the emerging medical and recreational cannabis industry in Canada. The range of topics include: law and regulations, public health and safety, finance and banking, public and government relations, as well as marketing and advertising. He will also participate in workshops on navigating the license application process; marketing and branding cannabis; PR and GR for cannabis; and leveraging data analysis.

Dr. Franciosi indicated, "These conferences will inform Veritas about new cannabis research and investment, as well as provide an update on the legalization and public health & safety concerns of medicinal cannabis from a Canadian perspective."

Also, Veritas Pharma is pleased with the Canadian government's recent announcement about the proposed legislation for the legalization of adult-use cannabis in Canada on or before July 1, 2018. Dr. Franciosi stated, 'it's a significant step toward the legalization and regulation of cannabis, with the potential to do more product development to confirm cannabis's efficacy as a legitimate alternative to drugs such as opioids. According to Deloitte, the market for marijuana products and services in Canada is estimated to be $22.6 billion when legalized (Business Insider/Toronto Star - Oct. 2016)".

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas' investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors; Veritas Pharma Inc.

"Dr. Lui Franciosi"

Dr. Lui Franciosi

Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com

Investor and Public Relations Contact

Veritas Pharma Inc.

Sam Eskandari

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.